Australian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of seasonal influenza vaccines in 2017

Australia
NITAGs
6 March 2017

During its 62nd meeting in February 2017, ATAGI endorsed its recommendation for annual influenza vaccination for any person ≥6 months of age who wishes to reduce the likelihood of becoming ill with influenza.

drapeau-australie.jpg

Key points:

  • Annual vaccination is the most important measure to prevent influenza and its complications.
  • Annual influenza vaccination is recommended for any person ≥6 months of age who wishes to reduce the likelihood of becoming ill with influenza.
  • Recent evidence suggests protection against influenza may start to decrease from 3 to 4 months following vaccination and early vaccination needs to be balanced with this. While influenza continues to circulate, it is never too late to vaccinate.
  • Only quadrivalent influenza vaccines (QIV) formulations are available in Australia in 2017. Age restrictions apply according to vaccine brand (refer to Table 1).
  • QIVs are funded on the National Immunisation Program (NIP) in 2017 for the following groups:
    • Aboriginal and/or Torres Strait Islander children aged 6 months to <5 years
    • Aboriginal and/or Torres Strait Islander persons aged ≥15 years
    • All persons aged ≥65 years
    • All persons aged ≥6 months who have certain medical conditions which increase the isk of influenza disease complications; for example, severe asthma, lung or heart disease, low immunity or diabetes (refer to Table 3).
    • Pregnant women (during any stage of pregnancy).
  • Influenza vaccination is also strongly recommended, but not funded, for other groups who are at increased risk of influenza and its complications (refer to Table 3 footnote).
  • Persons with egg allergy, including anaphylaxis, can be safely vaccinated with influenza vaccines. Persons with a history of anaphylaxis to egg can be vaccinated with a full vaccine dose in medical facilities with staff experienced in recognising and treating anaphylaxis.
  • Providers are reminded to report all vaccines given to the Australian Immunisation Register.
Documents to download

Related News & Events

  • Germany
    NITAGs

    Digital communication for NITAGs is no longer optional!

    25.10.2016

    In September 2016, STIKO, the German NITAG, launched its own app, the first of its kind in the NITAG community. Anyone can download the app, which is compatible with Android or IOS, and access all STIKO’s recommendations. “This innovative digital project aims to strengthen relationships between healthcare workers and STIKO,” explain Ole Wichmann and Judith Koch from Robert Koch Institute. 

    Read more
  • Congo (Democratic Republic of)
    NITAGs

    DRC is the 2nd country in Central Africa to establish a NITAG

    20.10.2016

    By Ministerial decree No. 1250 / CAB / MIN / SP / 014 / CD / 2016 dated of 17th October 2016, DRC becomes the 2nd country in Central Africa after Cameroon with a Technical Advisory Group on Immunization.

    Read more
  • Senegal
    NITAGs

    Introduction of the Meningococcal A Conjugate Vaccine into routine immunization in Senegal: the NITAG is getting ready

    18.10.2016

    Requested by the Minister of Health to issue a recommendation on the introduction of the Meningococcal A Conjugate Vaccine into routine immunization, the Advisory Committee on Immunization in Senegal (CCVS) has established a working group to prepare a technical dossier to guide experts in their deliberations. The Working Group (WG) met in a workshop in Mbour from 12th to 14th October 2016.

    With technical support from SIVAC initiative of HPID Center, the working group finalized the recommendation framework which specify critical data to support Senegal NITAG opinion on the relevance of the introduction of the meningococcal A conjugate vaccine into routine childhood immunization in Senegal. The working group also identified relevant studies from which evidence will be collected. The quality of this evidence will be assessed and data synthesized and analysed to prepare a strong technical dossier which will later form a basis for experts to make an informed decision on the subject. 

    Read more